MS023 dihydrochloride NEW
| Price | $77 | $108 | $179 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: MS023 dihydrochloride | CAS No.: 1992047-64-9 |
| Purity: 99.99% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | MS023 dihydrochloride |
| Description | MS023 dihydrochloride (MS023 2HCl) is a selective, cytosolic and highly potent inhibitor of human type I protein arginine methyltransferases (PRMTs) with antitumour activity, inhibits PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, and increases the proliferative capacity of isolated cultured MuSC. It can be used to study breast cancer. |
| In vitro | MS023 dihydrochloride (1-1000 nM) effectively and concentration-dependently reduces PRMT1 methyltransferase activity in MCF7 cells[1]. |
| In vivo | In NOD-scid IL2Rgnull (NSG) mice bearing primary MLL-r ALL cells, combinatorial treatment with MS023 dihydrochloride (160 mg/kg, ip) and PKC412 (100 mg/kg, i.g.) for 4 weeks extended the survival of leukemic mice compared to single treatments[2]. |
| Storage | Store under nitrogen Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 20 mg/mL (55.51 mM), Sonication is recommended. DMSO : 100 mg/mL (277.53 mM), Sonication is recommended. |
| Keywords | PRMT8 | PRMT6 | PRMT4 | PRMT3 | PRMT1 | HistoneMethyltransferase | Histone Methyltransferase |
| Inhibitors Related | MAK-683 hydrochloride | SNDX-5613 | Tazemetostat | Piribedil | XY1 | UNC 0631 | （Iso）-Flavokawain A | EPZ015666 | iso-Azalansta | AMI-1 free acid | MS37452 | MRTX-1719 |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Anti-Breast Cancer Compound Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | High-Efficiency Gene Editing Small Molecule Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $339.00 |
VIP6Y
|
Shanghai UCHEM Inc.
|
2026-06-26 | |
| $1.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 | |
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY